

We claim:

5

10

15

20

25

30

1. A modified anti-viral peptide comprising:
a peptide that exhibits anti-viral activity, and
a reactive group which is reactive with amino groups, hydroxyl groups, or
thiol groups on blood components to form stable covalent bonds.

2. The modified peptide of claim 1 wherein said reactive group is a
succinimidyl or a maleimido group.

3. The modified peptide of claim 1 wherein said reactive group is a
maleimido group which is reactive with a thiol group on a blood protein.

4. The modified peptide of claim 1 wherein said peptide is DP178 or
DP107 or analogs thereof.

5. The modified peptide of claim 1 wherein said peptide exhibits anti-
viral activity against human immunodeficiency virus (HIV).

6. The modified peptide of claim 5 wherein said peptide is selected
from the group consisting of SEQ ID NO:1 to SEQ ID NO:9.

7. The modified peptide of claim 5 wherein said peptide is DP 178 or
DP 107.

8. The modified peptide of claim 1 wherein said peptide exhibits anti-
viral activity against human respiratory syncytial virus (RSV).

9.

The modified peptide of claim 8 wherein said peptide is selected
from the group consisting of SEQ ID NO:10 to SEQ ID NO:30.

10. The modified peptide of claim 8 wherein said peptide is selected from the group consisting of SEQ ID NO:14 to SEQ ID NO:17 and SEQ ID NO:29.

5

11. The modified peptide of claim 1 wherein said peptide exhibits anti-viral activity against human parainfluenza virus (HPIV).

10 12. The modified peptide of claim 11 wherein said peptide is selected from the group consisting of SEQ ID NO:31 to SEQ ID NO:62.

15 13. The modified peptide of claim 11 wherein said peptide is selected from the group consisting of SEQ ID NO: 35, SEQ ID NO:38 to SEQ ID NO:42, SEQ ID NO:52 and SEQ ID NO:58.

14. The modified peptide of claim 1 wherein said peptide exhibits anti-viral activity against measles virus (MeV).

20 15. The modified peptide of claim 14 wherein said peptide is selected from the group consisting of SEQ ID NO:74 to SEQ ID NO:86.

25 16. The modified peptide of claim 14 wherein said peptide is selected from the group consisting of SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81 and SEQ ID NO:84.

17. The modified peptide of claim 1 wherein said peptide exhibits anti-viral activity against simian immunodeficiency virus (SIV).

30 18. The modified peptide of claim 17 wherein said peptide is selected from the group consisting of SEQ ID NO:63 to SEQ ID NO:73.

19. A composition for use in the prevention and/or treatment of acquired immune deficiency syndrome (AIDS) comprising a peptide that exhibits anti-viral activity against human immunodeficiency virus (HIV), modified with a reactive group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds.

5

20. The composition of claim 19 wherein said reactive group is a maleimido group which is reactive with a thiol group on a blood protein.

10

21. The composition of claim 20 wherein said peptide is DP178 or DP107 or analogs thereof.

15

22. A composition for use in the prevention and/or treatment of human respiratory syncytial virus (RSV) infection comprising a peptide that exhibits anti-viral activity against RSV, modified with a reactive group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds.

20

23. The composition of claim 22 wherein said reactive group is a maleimido group which is reactive with a thiol group on a blood protein.

25

24. The composition of claim 23 wherein said peptide is selected from the group consisting of SEQ ID NO:14 to SEQ ID NO:17 and SEQ ID NO:29.

25

25. A composition for use in the prevention and/or treatment of human parainfluenza virus (HPIV) infection comprising a peptide that exhibits anti-viral activity against human parainfluenza (HPIV), modified with a reactive group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds.

30

26. The composition of claim 25 wherein said reactive group is a maleimido group which is reactive with a thiol group on a blood protein.

5 27. The composition of claim 26 wherein said peptide is selected from the group consisting of SEQ ID NO: 35, SEQ ID NO:38 to SEQ ID NO:42, SEQ ID NO:52 and SEQ ID NO:58.

10 28. A composition for use in the prevention and/or treatment of measles virus (MeV) infection comprising a peptide that exhibits anti-viral activity against measles virus (MeV), modified with a reactive group which is reactive with amino groups, hydroxyl groups, or thiol groups on blood components to form stable covalent bonds.

15 29. The composition of claim 28 wherein said reactive group is a maleimido group which is reactive with a thiol group on a blood protein.

20 30. The composition of claim 29 wherein said peptide is selected from the group consisting of SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81 and SEQ ID NO:84.

add 987